BACKGROUND AND PURPOSE: The Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) established guidelines to increase safety in acute stroke thrombolysis, but precluding treatment in an important proportion of patients. We aimed to assess safety/efficacy of thrombolysis in patients with SITS-MOST exclusion criteria. METHODS: 369 nonlacunar tPA-treated patients were studied. Patients were classified as SITS-MOST (SM) or non-SITS-MOST (NSM) according to SITS-MOST-criteria fulfilling. Clinical evaluation was assessed by NIHSS and functional outcome by mRS at 3 months (functional independency=mRS <or=2). RESULTS: Baseline NIHSS was 17. 169 (45.8%) patients were SM and 200 (54.1%) NSM. Recanalization (47.6%/50.3%, P=0.36), 24-hour-improvement (55.6%/49.5%, P=0.114), and SICH were similar (4.8%/5.1%, P=0.554). At discharge, clinical improvement in SM-group was higher (66.7%/55.7%, P=0.024). NSM tended to higher mortality (10.5%/16.1%, P=0.084) and lower functional independence (48.7%/39.6%, P=0.082). CONCLUSIONS: Thrombolysis may be safe in patients not fulfilling SITS-MOST criteria. Testing thrombolysis in patients outside SITS-MOST could be considered in the future.
BACKGROUND AND PURPOSE: The Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) established guidelines to increase safety in acute stroke thrombolysis, but precluding treatment in an important proportion of patients. We aimed to assess safety/efficacy of thrombolysis in patients with SITS-MOST exclusion criteria. METHODS: 369 nonlacunar tPA-treated patients were studied. Patients were classified as SITS-MOST (SM) or non-SITS-MOST (NSM) according to SITS-MOST-criteria fulfilling. Clinical evaluation was assessed by NIHSS and functional outcome by mRS at 3 months (functional independency=mRS <or=2). RESULTS: Baseline NIHSS was 17. 169 (45.8%) patients were SM and 200 (54.1%) NSM. Recanalization (47.6%/50.3%, P=0.36), 24-hour-improvement (55.6%/49.5%, P=0.114), and SICH were similar (4.8%/5.1%, P=0.554). At discharge, clinical improvement in SM-group was higher (66.7%/55.7%, P=0.024). NSM tended to higher mortality (10.5%/16.1%, P=0.084) and lower functional independence (48.7%/39.6%, P=0.082). CONCLUSIONS: Thrombolysis may be safe in patients not fulfilling SITS-MOST criteria. Testing thrombolysis in patients outside SITS-MOST could be considered in the future.
Authors: Felipe De Los Rios; Dawn O Kleindorfer; Amy Guzik; Santiago Ortega-Gutierrez; Navdeep Sangha; Gyanendra Kumar; James C Grotta; Jin-Moo Lee; Brett C Meyer; Lee H Schwamm; Pooja Khatri Journal: J Stroke Cerebrovasc Dis Date: 2014-08-10 Impact factor: 2.136
Authors: Lee S Chung; Aleksander Tkach; Erin M Lingenfelter; Sarah B Dehoney; Jeannie Rollo; Adam de Havenon; L Dana DeWitt; Matthew R Grantz; Haimei Wang; Jana J Wold; Peter M Hannon; Natalie R Weathered; Jennifer J Majersik Journal: J Stroke Cerebrovasc Dis Date: 2015-12-11 Impact factor: 2.136
Authors: Matthew E Ehrlich; Li Liang; Haolin Xu; Andrzej S Kosinski; Adrian F Hernandez; Lee H Schwamm; Eric E Smith; Gregg C Fonarow; Deepak L Bhatt; Eric D Peterson; Ying Xian Journal: Stroke Date: 2019-04-30 Impact factor: 7.914
Authors: Eivind Berge; William Whiteley; Heinrich Audebert; Gian Marco De Marchis; Ana Catarina Fonseca; Chiara Padiglioni; Natalia Pérez de la Ossa; Daniel Strbian; Georgios Tsivgoulis; Guillaume Turc Journal: Eur Stroke J Date: 2021-02-19
Authors: Mohammed H Alanazy; Rima B Barakeh; Alanood Asiri; Maha F Edrees; Ahmad R Abuzinadah; Bandar N Aljafen; Taim Muayqil Journal: Neurol Res Int Date: 2018-02-13
Authors: Yi Dong; Wenjie Cao; Jinma Ren; Deepak S Nair; Sarah Parker; Jan L Jahnel; Teresa G Swanson-Devlin; Judith M Beck; Maureen Mathews; Clayton J McNeil; Manas Upadhyaya; Yuan Gao; Qiang Dong; David Z Wang Journal: PLoS One Date: 2015-08-06 Impact factor: 3.240